StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$17.83−0.49 (-2.67%)

Close on Nov 18, 2026Market cap $3.07BP/E 8.1Yield –

Acadia Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Acadia Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $1.14B, up 11.8% year over year. For fiscal 2025 it was $1.07B, up 11.9% from the year before. Over ten years it grew 165.7% a year on average. The highest annual figure on record is $1.07B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.07B+11.9%
FY2024Dec 31, 2024$957.80M+31.8%
FY2023Dec 31, 2023$726.44M+40.4%
FY2022Dec 31, 2022$517.24M+6.8%
FY2021Dec 31, 2021$484.15M+9.6%
FY2020Dec 31, 2020$441.76M+30.3%
FY2019Dec 31, 2019$339.08M+51.5%
FY2018Dec 31, 2018$223.81M+79.2%
FY2017Dec 31, 2017$124.90M+620.7%
FY2016Dec 31, 2016$17.33M+28311.5%
FY2015Dec 31, 2015$61.00K-49.2%
FY2014Dec 31, 2014$120.00K-89.5%
FY2013Dec 31, 2013$1.15M-76.7%
FY2012Dec 31, 2012$4.91M+137.4%
FY2011Dec 31, 2011$2.07M-95.1%
FY2010Dec 31, 2010$42.14M+558.5%
FY2009Dec 31, 2009$6.40M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$307.96M+16.4%
Q1 FY2026Mar 31, 2026$268.06M+9.7%
Q4 FY2025Dec 31, 2025$283.99M+9.4%
Q3 FY2025Sep 30, 2025$278.63M+11.3%
Q2 FY2025Jun 30, 2025$264.57M+9.3%
Q1 FY2025Mar 31, 2025$244.32M+18.7%
Q4 FY2024Dec 31, 2024$259.60M+12.4%
Q3 FY2024Sep 30, 2024$250.40M+18.3%
Q2 FY2024Jun 30, 2024$241.96M+46.4%
Q1 FY2024Mar 31, 2024$205.83M+73.8%
Q4 FY2023Dec 31, 2023$231.04M+69.3%
Q3 FY2023Sep 30, 2023$211.70M+62.0%
Q2 FY2023Jun 30, 2023$165.24M+22.8%
Q1 FY2023Mar 31, 2023$118.46M+2.6%
Q4 FY2022Dec 31, 2022$136.49M+4.4%
Q3 FY2022Sep 30, 2022$130.71M-0.7%
Q2 FY2022Jun 30, 2022$134.56M+16.8%
Q1 FY2022Mar 31, 2022$115.47M+8.4%
Q4 FY2021Dec 31, 2021$130.76M+8.1%
Q3 FY2021Sep 30, 2021$131.61M+9.2%
Q2 FY2021Jun 30, 2021$115.22M+4.6%
Q1 FY2021Mar 31, 2021$106.55M+18.3%
Q4 FY2020Dec 31, 2020$121.01M+23.1%
Q3 FY2020Sep 30, 2020$120.58M+27.5%
Q2 FY2020Jun 30, 2020$110.10M+32.3%
Q1 FY2020Mar 31, 2020$90.07M+43.1%
Q4 FY2019Dec 31, 2019$98.33M+65.1%
Q3 FY2019Sep 30, 2019$94.59M+62.2%
Q2 FY2019Jun 30, 2019$83.21M+45.8%
Q1 FY2019Mar 31, 2019$62.96M+28.8%
Q4 FY2018Dec 31, 2018$59.57M+36.7%
Q3 FY2018Sep 30, 2018$58.31M+63.9%
Q2 FY2018Jun 30, 2018$57.06M+87.2%
Q1 FY2018Mar 31, 2018$48.87M+219.7%
Q4 FY2017Dec 31, 2017$43.56M+264.2%
Q3 FY2017Sep 30, 2017$35.58M+575.4%
Q2 FY2017Jun 30, 2017$30.48M–
Q1 FY2017Mar 31, 2017$15.29M–
Q4 FY2016Dec 31, 2016$11.96M–
Q3 FY2016Sep 30, 2016$5.27M–

More Acadia Pharmaceuticals figures

See a number that looks wrong?